{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:09:33Z","timestamp":1778778573609,"version":"3.51.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["24CDA1271837"],"award-info":[{"award-number":["24CDA1271837"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"DOI":"10.1186\/s40959-026-00474-2","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T09:44:28Z","timestamp":1778319868000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world prevalence and outcome of elevated right ventricular systolic pressure in myelofibrosis"],"prefix":"10.1186","volume":"12","author":[{"given":"Alexis Behne","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elicia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sruthi","family":"Selvakumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himara","family":"Koelmeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanath","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinley","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianxing","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teagen","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Austin","family":"Chao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carson","family":"Balen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gowtam","family":"Mannam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Yudiono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Lien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sami","family":"Khatib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varshith","family":"Paduchuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najla","family":"Al Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinming","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey E.","family":"Lancet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Alomar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Cleveland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Kuykendall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami S.","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seongseok","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"9","key":"474_CR1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.clml.2019.05.009","volume":"19","author":"M Austin","year":"2019","unstructured":"Austin M, Quesenberry PJ, Ventetuolo CE, Liang O, Reagan JL. Prevalence and effect on survival of pulmonary hypertension in myelofibrosis. Clin Lymphoma Myeloma Leuk. 2019;19(9):593\u20137.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"474_CR2","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12185-022-03454-1","volume":"117","author":"O Leiva","year":"2023","unstructured":"Leiva O, Ren S, Neuberg D, et al. Pulmonary hypertension is associated with poor cardiovascular and hematologic outcomes in patients with myeloproliferative neoplasms and cardiovascular disease. Int J Hematol. 2023;117(1):90\u20139.","journal-title":"Int J Hematol"},{"issue":"2","key":"474_CR3","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/ejh.13543","volume":"106","author":"A Ferrari","year":"2021","unstructured":"Ferrari A, Scandura J, Masciulli A, Krichevsky S, Gavazzi A, Barbui T. Prevalence and risk factors for pulmonary hypertension associated with chronic myeloproliferative neoplasms. Eur J Haematol. 2021;106(2):250\u20139.","journal-title":"Eur J Haematol"},{"issue":"4","key":"474_CR4","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00277-020-03962-2","volume":"99","author":"J Lopez-Mattei","year":"2020","unstructured":"Lopez-Mattei J, Verstovsek S, Fellman B, et al. Prevalence of pulmonary hypertension in myelofibrosis. Ann Hematol. 2020;99(4):781\u20139.","journal-title":"Ann Hematol"},{"key":"474_CR5","doi-asserted-by":"publisher","unstructured":"Leiva O, Soo S, Liu O, et al. Characterization and prognostic implication of pulmonary hypertension among patients with myeloproliferative neoplasms. Haematologica. 2025;110(10). https:\/\/doi.org\/10.3324\/haematol.2025.287497.","DOI":"10.3324\/haematol.2025.287497"},{"issue":"2","key":"474_CR6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jaccao.2022.04.002","volume":"4","author":"O Leiva","year":"2022","unstructured":"Leiva O, Hobbs G, Ravid K, Libby P. Cardiovascular disease in myeloproliferative neoplasms: JACC: CardioOncology State-of-the-art review. JACC CardioOncol. 2022;4(2):166\u201382.","journal-title":"JACC CardioOncol"},{"issue":"3","key":"474_CR7","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.healun.2014.09.009","volume":"34","author":"EC Roach","year":"2015","unstructured":"Roach EC, Park MM, Tang WH, et al. Impaired right ventricular-pulmonary vascular function in myeloproliferative neoplasms. J Heart Lung Transpl. 2015;34(3):390\u20134.","journal-title":"J Heart Lung Transpl"},{"issue":"9","key":"474_CR8","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1161\/CIRCULATIONAHA.109.933762","volume":"122","author":"E Soon","year":"2010","unstructured":"Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation. 2010;122(9):920\u20137.","journal-title":"Circulation"},{"issue":"3","key":"474_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.echo.2025.01.006","volume":"38","author":"M Mukherjee","year":"2025","unstructured":"Mukherjee M, Rudski LG, Addetia K, et al. Guidelines for the Echocardiographic assessment of the right heart in adults and special considerations in pulmonary hypertension: recommendations from the American society of echocardiography. J Am Soc Echocardiogr. 2025;38(3):141\u201386.","journal-title":"J Am Soc Echocardiogr"},{"issue":"7","key":"474_CR10","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.echo.2010.05.010","volume":"23","author":"LG Rudski","year":"2010","unstructured":"Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American society of echocardiography endorsed by the European association of echocardiography, a registered branch of the European society of cardiology, and the Canadian society of echocardiography. J Am Soc Echocardiogr. 2010;23(7):685\u2013713. quiz 786\u2009\u2013\u2009688.","journal-title":"J Am Soc Echocardiogr"},{"issue":"19","key":"474_CR11","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1002\/cncr.34414","volume":"128","author":"AT Kuykendall","year":"2022","unstructured":"Kuykendall AT, Mo Q, Sallman DA, et al. Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlates. Cancer. 2022;128(19):3495\u2013501.","journal-title":"Cancer"},{"issue":"1","key":"474_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00277-023-05564-0","volume":"103","author":"NP Horvat","year":"2024","unstructured":"Horvat NP, Abdallah EF, Xie Z, et al. Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities. Ann Hematol. 2024;103(1):117\u201323.","journal-title":"Ann Hematol"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-026-00474-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00474-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00474-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:22:08Z","timestamp":1778775728000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40959-026-00474-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["474"],"URL":"https:\/\/doi.org\/10.1186\/s40959-026-00474-2","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"23 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TN: Clinical trial support to the institution by Novartis, Clinical trial support (drug only supply) to the institution by Karyopharm, Consultant to Alexion. JEL: Consultancy: Dedham Group, Jasper Therapeutics, Astellas, Dava Oncology, Novartis, Agios\/Servio, Boxer Capital, Jazz, BerGenBio, Millenium Pharma\/ Takeda, ElevateBio Management, Daiichi Sankyo, AbbVie, Servier; Research Funding: Syntrix Pharmaceuticals, Celgene\/ Bristol Myers Squibb.AK: Research Support: Protagonist, Blueprint Medicines Corporation, GSK - Sierra Oncology, Prelude Pharmaceuticals, Bristol Myers Squibb, Morphosys; Consultancy: Imago Biosciences, Incyte, Blueprint Medicines Corporation, Novartis, Abbvie, GSK - Sierra Oncology, Bristol Myers Squibb, PharmaEssentia, CTI Biopharma; Honoraria: Imago Biosciences, Incyte, Blueprint Medicines Corporation, Novartis, Abbvie, GSK - Sierra Oncology, Bristol Myers Squibb, PharmaEssentia, CTI Biopharma; Speakers Bureau: Imago Biosciences, Incyte, Blueprint Medicines Corporation, Novartis, Abbvie, GSK - Sierra Oncology, Bristol Myers Squibb, PharmaEssentia, CTI Biopharma. RK: Consultancy\/honoraria: Servier, Geron, Bristol Myers Squibb , Sbio, PharmaEssentia, Rigel Speakers Bureau: Servier, Sbio , Pharma Essentia, RigelDHL: Consultant fee from Lexicon PharmaceuticalsThe remaining authors decare that they have no competing interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}